KNSA
Kiniksa Pharmaceuticals, Ltd.
NASDAQ · Healthcare · Biotechnology · BM
$77.91
−3.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 840.8M | 677.6M | 423.2M | 270.3M | 220.2M |
| Cost of Revenue | 382.7M | 307.4M | 60.9M | 56.5M | 22.9M |
| Gross Profit | 458.1M | 370.1M | 362.3M | 213.7M | 197.3M |
| Operating Expenses | |||||
| R&D Expense | 127.1M | 96.9M | 111.6M | 76.1M | 65.5M |
| SG&A Expense | 230.9M | 196.3M | 168.0M | 129.4M | 98.0M |
| General & Admin Expense | 63.9M | — | 156.6M | — | — |
| Selling & Marketing Expense | — | — | 11.4M | — | — |
| Other Expenses | — | — | 128.3M | 33.4M | 24.1M |
| Total Operating Expenses | 357.9M | 292.9M | 407.9M | 238.9M | 187.5M |
| Cost and Expenses | 740.6M | 600.3M | 468.9M | 295.5M | 210.4M |
| Operating Income (EBIT) | 100.3M | 77.2M | (45.6M) | (25.2M) | 9.8M |
| Non-Operating | |||||
| Interest Income | 13.2M | 11.6M | 9.5M | 8.5M | 1.3M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 13.2M | 11.6M | 9.5M | 8.5M | 1.3M |
| Other Non-Op Income/Expense | 14.0M | 11.6M | 9.5M | 8.5M | 1.3M |
| Non-Operating Income (excl Interest) | (10.1M) | (11.6M) | (9.5M) | (8.5M) | (1.3M) |
| EBT (Pre-Tax Income) | 114.3M | 88.9M | (36.2M) | (16.7M) | 11.0M |
| Income Tax Expense | 33.6M | 29.9M | 7.0M | (30.7M) | (172.3M) |
| Bottom Line | |||||
| Net Income | 80.7M | 59.0M | (43.2M) | 14.1M | 183.4M |
| Earnings from Cont. Ops | 80.7M | 59.0M | (43.2M) | 14.1M | 183.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 80.7M | 59.0M | (43.2M) | 14.1M | 183.4M |
| Per Share | |||||
| Basic EPS | $1.07 | $0.80 | ($0.60) | $0.20 | $2.64 |
| Diluted EPS | $0.98 | $0.75 | ($0.60) | $0.20 | $2.60 |
| Revenue Per Share | $10.84 | $9.13 | $5.93 | $3.86 | $3.17 |
| Shares | |||||
| Basic Shares Outstanding | 77.6M | 74.2M | 71.4M | 70.1M | 69.4M |
| Diluted Shares Outstanding | 83.4M | 79.0M | 71.4M | 71.9M | 70.4M |
| Profitability Metrics | |||||
| EBITDA | 112.1M | 90.4M | (34.5M) | (14.3M) | 13.4M |
| D&A | 1.8M | 1.6M | 1.7M | 2.3M | 2.4M |
| EBIT | 110.3M | 88.9M | (36.2M) | (16.7M) | 11.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026